Merus Labs International (TSE:MSL) Rating Increased to Moderate Buy at Canaccord Genuity Group

Canaccord Genuity Group upgraded shares of Merus Labs International (TSE:MSL) (NASDAQ:MSLI) to a moderate buy rating in a research report report published on Thursday,Zacks.com reports.

Several other equities research analysts also recently commented on the company. Cantor Fitzgerald raised Merus Labs International to a “strong-buy” rating in a report on Wednesday, March 11th. Guggenheim raised Merus Labs International to a “strong-buy” rating in a report on Tuesday, April 28th. Finally, Leerink Partners raised Merus Labs International to a “strong-buy” rating in a report on Monday, April 6th. Three research analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a fifty-two week low of C$0.95 and a fifty-two week high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.